抗VEGF药物联合青光眼引流阀植入在新生血管性青光眼治疗中的应用价值研究

Application Value of Anti-VEGF Drugs Combined with Glaucoma Drainage Valve Implantation in the Treatment of Neovascular Glaucoma

目的研究新生血管性青光眼用抗VEGF和青光眼引流阀植入治疗的价值。方法在2018年3月-2019年6月期间,简单随机选取该院收治60例新生血管性青光眼患者,将60例患者作为研究对象,按照是否行VEGF药物注射将他们分为两组:注射组(30例)和未注射组(30例),术后随访了5次(术后1 d、术后1周、术后1个月、术后3个月、术后6个月。比较应用价值。结果和未注射组相比,注射组患者在5次随访时间点眼压均低于未注射组(P<0.05);注射组患者视力提高率(86.67%)优于未注射组患者视力提高率(63.33%),组间差异有统计学意义(χ^2=4.356,P=0.037);注射组患者的术后并发症总发生率(10.00%)低于未注射组的总发生率(40.00%),组间差异有统计学意义(χ^2=7.200,P=0.007)。结论新生血管性青光眼经过抗VEGF和青光眼引流阀植入治疗效果明显,既能更好的控制眼压、提高视力,还减少了术后并发症,是治疗新生血管性青光眼的有效方法。

Objective To study the value of anti-VEGF and glaucoma drainage valve implantation for neovascular glaucoma.Methods From March 2018 to June 2019,60 patients with neovascular glaucoma were convenient selection treated in the hospital.60 patients were taken as the research object,and they were divided into two groups according to whether they received VEGF injection:injection group(30 patients)and non-injected group(30 cases),followed up five times postoperatively(1 d,1 week,1 month,3 months,and 6 months after operation).Comparison of application value.Results Compared with the injection group,the IOP of the injection group was lower than that of the non-injection group at 5 follow-up points(P<0.05);the visual acuity improvement rate of the injection group(86.67%)was better than that of the non-injection group(63.33%),and the difference was statistically significant(χ^2=4.356,P=0.037);the total incidence of postoperative complications(10.00%)in patients in the injection group was lower than the total incidence(40.00%)in the non-injection group,and the difference was statistically significant(χ^2=7.200,P=0.007).Conclusion The treatment of neovascular glaucoma with anti-VEGF and glaucoma drainage valve implantation has obvious effects,which can better control intraocular pressure,improve vision,and reduce postoperative complications.It is an effective method for treating neovascular glaucoma.